Omega 3 fatty acid - JeniVision
Alternative Names: JV-MD2Latest Information Update: 03 Jan 2024
At a glance
- Originator JeniVision
- Class Anti-inflammatories; Eye disorder therapies; Neuroprotectants; Omega 3 fatty acids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Age-related macular degeneration; Eye disorders; Neurodegenerative disorders; Ocular inflammation; Retinopathy of prematurity
Most Recent Events
- 03 Jan 2024 JeniVision plans a phase III trial for Retinal diseases (Ophthalmic) (JeniVision pipeline, January 2024)
- 11 Oct 2022 Omega 3 fatty acid - JeniVision is available for licensing as of 11 Oct 2022 (Jenivision pipeline)
- 11 Oct 2022 Preclinical trials in Neurodegenerative disorders in USA (unspecified route) (JeniVision pipeline, before October 2022)